REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Deep Sleep Stack

Sleep Optimizationbeginner

86

synergy

86
Share
Peptides

2

Avg Daily mcg

200

Level

beginner

Added

May 17, 2026

Overview

The Deep Sleep Stack combines DSIP with low-dose Ipamorelin to create a powerful sleep-enhancement protocol that simultaneously promotes restorative sleep and maximizes the nocturnal growth hormone surge. DSIP acts on multiple neurotransmitter systems to promote slow-wave sleep initiation and maintenance. It modulates GABAergic and glutamatergic signaling, normalizes disrupted circadian cortisol rhythms, and promotes melatonin secretion from the pineal gland. Unlike pharmaceutical sleep aids that often suppress deep sleep (many benzodiazepines and Z-drugs preferentially enhance Stage 2 rather than Stage 3/4 sleep), DSIP specifically promotes the delta-wave activity that characterizes the most restorative sleep phases. Ipamorelin at the low 100mcg dose serves a dual purpose in this stack. First, GH secretagogue activity at bedtime amplifies the natural nocturnal GH pulse — the largest pulse occurs 60-90 minutes after sleep onset and is responsible for the majority of daily GH production. Second, the GH release itself promotes deeper slow-wave sleep through a positive feedback mechanism: GH-releasing neurons in the hypothalamus are interconnected with sleep-promoting neurons, creating bidirectional enhancement. The practical benefit of this combination extends beyond sleep quality: during enhanced slow-wave sleep, the glymphatic system (the brain''s waste clearance mechanism) operates at maximum efficiency, clearing metabolic byproducts and amyloid-beta that accumulate during waking hours. Growth hormone during sleep drives tissue repair, immune function, and memory consolidation. Users typically report falling asleep faster, experiencing fewer night awakenings, and waking with noticeably better energy and cognitive clarity. The protocol should be administered 30-60 minutes before intended sleep time on an empty stomach for optimal peptide absorption and GH release.

Dosing Protocol

DSIP

nightly· subcutaneous

Read more about DSIP →

100 mcg

per dose

Ipamorelin

nightly· subcutaneous

Read more about Ipamorelin →

100 mcg

per dose

Goals & Evidence

Deep sleepSleep qualityGH releaseRecoveryREM optimization
Evidence tier:Human Data

Warnings

  • DSIP timing is critical — administer 30-60 min before bed. Ipamorelin is Cat 2. Do not combine with sleep medications without physician guidance.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.